A5103004608- Nonmelanoma Skin Cancer Studies
- Cutaneous Melanoma Detection and Management
- Cutaneous lymphoproliferative disorders research
- Cancer and Skin Lesions
- Skin Protection and Aging
- Photodynamic Therapy Research Studies
- Molecular Biology Techniques and Applications
- Infectious Diseases and Mycology
- Cardiac tumors and thrombi
- Parathyroid Disorders and Treatments
- Traumatic Brain Injury Research
- Autoimmune Bullous Skin Diseases
- Tumors and Oncological Cases
- Sarcoma Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Vascular Tumors and Angiosarcomas
- Dermatological and Skeletal Disorders
- Economic and Financial Impacts of Cancer
- Microbial infections and disease research
- Radiation Dose and Imaging
- Trauma Management and Diagnosis
Edinburgh Royal Infirmary
2022-2025
University of Edinburgh
2021-2024
NHS Lothian
2021-2023
University of Glasgow
2016-2021
Monklands Hospital
2004-2019
NHS Lanarkshire
2018
Princess Royal Hospital
2006
St Mary's Hospital
2006
Royal Cornwall Hospital
2006
Manchester Royal Infirmary
2006
Background Actinic keratosis (AK), the most common premalignant skin condition, can represent a management challenge. Treatment should not only be effective, but also well tolerated and allow for good cosmesis on typical sun‐exposed highly visible body sites. Objectives The primary objective was to compare lesion response subject preference topical methyl aminolaevulinate (MAL)‐photodynamic therapy (PDT) vs. cryotherapy treatment of AK. Methods In this 24‐week, multicentre, randomized,...
Linked Comment: M.D. Moncrieff and J.P. Nobes. Br J Dermatol 2021; 185:877. Plain language summary available online
Abstract Background Actinic keratosis ( AK ) severity is currently evaluated by subjective assessment of patients. Objectives To develop and perform an initial pilot validation a new easy‐to‐use quantitative tool for assessing on the head. Methods The actinic area index AKASI head was developed based review other scoring systems in dermatology, particular psoriasis PASI ). Initial performed 13 physicians 18 patients two controls using physician global PGA . determine score, divided into four...
Common histological classification schemes of actinic keratoses (AK) do not evaluate growth patterns at basal epidermal aspects AK. Until now, the importance AK has been studied.To investigate extent atypical keratinocytes throughout epidermis and variation in AK.AK lesions occurring on head/face from patients seen routine practice were assessed histologically. We determined grade (AK I-III), (crowding, budding papillary sprouting) accompanying parameters.Of 246 included, 28.0%...
Basal cell carcinoma (BCC) represents the most common nonmelanoma skin cancer worldwide, affecting mainly adult, fair-skinned individuals. The World Health Organization distinguishes aggressive and nonaggressive forms, of which prototypical variants latter are primary nodular superficial BCC.To demonstrate noninferiority BF-200 ALA (a nanoemulsion gel containing 5-aminolaevulinic acid) compared with MAL cream methyl aminolaevulinate) in treatment BCC photodynamic therapy (PDT)....
In addition to the extent of atypical keratinocytes throughout epidermis, actinic keratoses (AKs) are histologically characterized by downward‐directed basal‐layer expansion. It is not known whether this growth pattern correlates with risk developing invasive squamous cell carcinoma (iSCC). To characterize prevalence expansion AKs adjacent iSCC. The epidermis overlying and iSCCs was assessed histologically. We determined histological grade (AK I–III), basal (PRO I–III) accompanying...
This case report describes a 71-year-old man with nodular amyloidosis (NA), rare form of primary localised cutaneous amyloidosis, presenting painful nodules on the toes. Histopathology confirmed NA, and extensive evaluation excluded systemic amyloidosis. highlights importance distinguishing NA from due to its poor prognosis.
Actinic keratoses (AKs) are commonly diagnosed clinically. keratosis area and severity index (AKASI) is a new easy-to-use tool to assess the of AKs on head.To determine association between chronically UV-induced tumours such as basal cell carcinomas (BCC) or squamous (SCC) AKASI.We performed retrospective analysis patients who had undergone oncological surgery due were assessed for AKASI Physician's global assessment (PGA) prior surgery. Statistical was evaluate correlation AKASI, PGA...
Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy actinic keratosis.Results with imiquimod 3.75% Background: Current parameters the keratosis (AK) treatments compare clinical at start and end study.However, sun-exposed field also contains subclinical which may become detectable during treatment.Lmax, maximum lesion count treatment, is to better assess AK therapies.Measuring using reduction Lmax includes first time clearance both...
Actinic keratoses (AKs) can histologically be classified by the extent of atypical keratinocytes throughout epidermis or their pattern basal proliferation. Currently, no data on inter-rater reliability both scores is available.To evaluate two classification schemes; histological grade (AK I-III) and proliferation (PRO I-III).Histological images 54 AKs were 21 independent dermatopathologists with regard to I-III), assumed risk progression into invasive carcinoma.Overall, 16.7% (9/54) as AK I,...
Please cite this paper as : Effectiveness of cross polarized light and fluorescence diagnosis for detection sub‐clinical clinical actinic keratosis during imiquimod treatment. Experimental Dermatology 2010; 19: 641–647. Background: During treatment (AK) lesions with often become visible. It is, however, unclear whether these would be detectable beforehand. Objective: The aim pilot study was to compare two techniques, photography (CPL) (FD) using methyllevulinic acid illumination Wood’s lamp...
Actinic keratoses (AK) are generally treated to reduce the risk of progression into invasive cutaneous squamous cell carcinoma (cSCC). However, this transformation is low, and rather than focusing on these lesions, current treatment studies report complete clearance AKs in an entire field. This study aimed investigate treatment-resistant (trAK) after field therapy compared randomly chosen prior treatment.AKs were clinically assessed according grade hyperkeratosis pain palpation, treatment....
Imiquimod 3.75% reduces 92.2% of all actinic keratosis (AK) lesions, assumed to include both subclinical and clinical across a large sun-exposed field such as the full face or balding scalp.To evaluate efficacy imiquimod using reduction in lesions from Lmax (the maximum lesion count during treatment) subgroups patients with low high AK counts.Patients two 14-week, placebo-controlled, double-blind studies were subgrouped according whether they had ≤ 10 >10 at baseline. Treatment was applied...
Abstract Background In patients with actinic keratosis ( AK ), subclinical and clinical lesions coexist across large areas of sun‐exposed skin. The long‐term efficacy treatments depends on their ability to eradicate both types the entire field. Objective To assess imiquimod 3.75% using reduction in from Lmax (maximum lesion count during treatment), which assesses clear lesions. Methods Patients 5–20 full face or balding scalp two 14‐week, randomized, vehicle‐controlled, double‐blind studies...
Cutaneous sarcomas comprise a broad group of rare, heterogeneous mesenchymal tumours. The present report describes single centre experience regarding the management and outcomes patients with superficial soft tissue (SSTS). Key prognostic factors in predicting overall survival (OS) local relapse‑free were determined. Data from 66 SSTS treated surgically within Edinburgh Lothian collected context service evaluation. Patient demographics, tumour specifics treatment, as well 5‑year OS...
<b><i>Background/Aims:</i></b> Actinic keratosis area and severity index (AKASI) is a new assessment tool to quantify the of actinic damage on head. Thus far, it has not been evaluated in monitoring efficacy field-directed topical treatments (AK) routine clinical practice. Thus, aim this study was determine treatment outcomes by using AKASI 3 months after initiation application diclofenac sodium 3% hyaluronic acid 2.5% gel (DFS) patients with AKs...